HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Chapter Taps Into P&G Product Development Capacity

This article was originally published in The Tan Sheet

Executive Summary

Six months after becoming a wholly owned subsidiary of Procter & Gamble, dietary supplement firm New Chapter is taking advantage of its parent company’s resources in innovation, ingredient sourcing, clinical trials and packaging, says New Chapter VP Graham Rigby.

You may also be interested in...



HBW Product Launches: New Chapter Collagen, Alkamind Acid-Kicking, GNC China, Tetra Bio Canada, More

GNC, Harbin launch supplements in China following regulatory approval; Bee Gone expands with allergy swabs; Bed, Bath & Beyond expands distribution of CBDMedic personal care products promoted by Rob Gronkowski; Tetra Bio has Canadian OK For hemorrhoid and pain relief OTCs, US and European pending; Agrozen offers Urban Daze CBD products; New Chapter portfolio expansion also includes fermented vitamins, elderberry supplements and magnesium; and Alkamind’s Acid-Kicking Coffee Alkalizer creamers help neutralize acid from coffee.

Procter & Gamble Opens New Chapter With Supplement Deal

Procter & Gamble buys Vermont-based whole foods supplement maker New Chapter Organics, expanding its consumer business and gaining a foothold in the natural products space. P&G intends to keep New Chapter a wholly owned subsidiary and leave most of its operations intact.

P&G Throws Weight Behind Consumer Growth After Shedding Pharma

Procter & Gamble faces several options - and some potential challenges - to grow its OTC portfolio using the resources gained in the sale of its prescription drug business

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel